SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Evidence-based guideline for risk stratification, empiric therapy, prophylaxis, and management of febrile neutropenia in cancer patients.
Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia, central line-associated bloodstream infections in neutropenic patients, infection prevention measures, and patient and caregiver education.
Fluoroquinolone prophylaxis, antifungal prophylaxis, antiviral and PJP prophylaxis, G-CSF primary and secondary prophylaxis with dosing and timing, therapeutic G-CSF in established febrile neutropenia, and management of persistent fever and documented infections.
Empiric intravenous antibiotic monotherapy and combination regimens with complete dosing, indications for vancomycin and anti-gram-positive agents, antibiotic de-escalation and duration criteria, outpatient eligibility for low-risk febrile neutropenia, oral antibiotic regimens, and monitoring requirements.
Definitions of febrile neutropenia, MASCC risk index, CISNE score, high-risk versus low-risk classification, and comprehensive initial workup including history, physical examination, laboratory studies, blood cultures, and imaging.